Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Parkinson' Disease Clear all
Completed Not applicable Interventional

The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients

NCT01769690
View directory record Official record
Conditions
Parkinson's Disease
Interventions
DBS stimulator setting alteration, virtual reality simulator
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Cognitive Training in Parkinson's Disease

NCT05495997
View directory record Official record
Conditions
Parkinson Disease
Interventions
Mental Imagery Training, Psychoeducation
Behavioral
Lead sponsor
Yale University
Other
Eligibility
40 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

An RCT of a Telemedicine Intervention for Hypokinetic Dysarthria in PD

NCT04617496
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Combined speech and exercise intervention, Health education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 4 Interventional

Donepezil to Treat Dementia in Parkinson's Disease

NCT00030979
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Study of LY300164 for the Treatment of Parkinson's Disease

NCT00004576
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease
Interventions
LY300164
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 5:37 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease

NCT06976268
View directory record Official record
Conditions
Parkinson Disease
Interventions
BHV-8000, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
40 Years to 85 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Farmington, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of a Breathwork Practice (SKY) on Well-Being of Individuals With Parkinson's Disease (iPD) and Care Partners

NCT06581523
View directory record Official record
Conditions
Parkinson's Disease
Interventions
SKY Breath and Meditation
Behavioral
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Coral Springs, Florida • Davie, Florida • Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Enrolling by invitation Phase 1 Interventional

Autologous iPSC-Derived Dopamine Neuron Transplantation for Parkinson's Disease

NCT06422208
View directory record Official record
Conditions
Parkinson Disease
Interventions
Autologous midbrain dopamine neurons
Biological
Lead sponsor
Penelope J. Hallett, Ph.D.
Other
Eligibility
55 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Pragmatic Cyclical Lower Extremity Exercise Trial for Parkinson's Disease

NCT04000360
View directory record Official record
Conditions
Parkinson Disease
Interventions
High-Intensity Aerobic Exercise (AE), Usual and Customary Care (UCC)
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Cleveland, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jun 26, 2026, 5:37 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Rhythmic Entrainment in Bilingual Speakers With Dysarthria

NCT03645265
View directory record Official record
Conditions
Parkinson Disease, Ataxia
Interventions
Auditory, Gestures
Behavioral
Lead sponsor
Herbert H. Lehman College, City University of New York
Other
Eligibility
21 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Jun 26, 2026, 5:37 AM EDT
Recruiting No phase listed Observational

Deep Brain Stimulation for Visuomotor Function in Parkinson's Disease

NCT05400499
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 1Phase 2 Interventional

Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)

NCT04700072
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Pembrolizumab/Quavonlimab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
9
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

NCT05508867
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
favezelimab/pembrolizumab, bendamustine, gemcitabine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Aerobic Exercise in Parkinson's Disease

NCT03808675
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Aerobic walking, Usual care with PD specific health education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 1Phase 2 Interventional

Behavioral Treatments for Anxiety and Depression in Veterans With Parkinson's Disease

NCT01323699
View directory record Official record
Conditions
Parkinson Disease, Anxiety, Depression
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 3 Interventional

Long Term Safety and Efficacy of SC Apomorphine in Treatment of "Off" Episodes in Late-Stage Parkinson's Disease

NCT00142545
View directory record Official record
Conditions
Parkinson Disease
Interventions
apomorphine HCl injection
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2005 · Synced Jun 26, 2026, 5:37 AM EDT
Terminated Not applicable Interventional Results available

Low Dose Niacin (Vitamin B3) for Parkinson's Disease

NCT03808961
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Niacin, Niacinamide, Placebo
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Jun 26, 2026, 5:37 AM EDT
Active, not recruiting No phase listed Observational

Clinical Laboratory Evaluation of Chronic Autonomic Failure

NCT03648905
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
Interventions
13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB), 18F-Dopamine
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 120 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Recruiting Phase 1Phase 2 Interventional

rTMS to Improve Cognition in Parkinson's

NCT03836950
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
MagVenture MagProX100 stimulator (MagVenture, Falun, Denmark)
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Hines, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Mindfulness Based Stress Reduction for Parkinson's Disease: A Longitudinal Study

NCT03998462
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Mindfulness Based Stress Reduction, Psychoeducational Supportive Care
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Jun 26, 2026, 5:37 AM EDT
Terminated Phase 1 Interventional Results available

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

NCT03099161
View directory record Official record
Conditions
Neoplasm
Interventions
preladenant, pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

Varenicline for Gait and Balance Impairment in Parkinson Disease

NCT01341080
View directory record Official record
Conditions
Parkinson Disease
Interventions
Varenicline, Sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 29, 2022 · Synced Jun 26, 2026, 5:37 AM EDT
Completed Phase 2 Interventional

Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease

NCT04506073
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Mesenchymal Stem Cells, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years to 79 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Jun 26, 2026, 5:37 AM EDT